Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Lung Cancer(2021)10.1016/j.lungcan.2021.11.021Source: DataRank Database

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer is a research paper published in Lung Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 36 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access36 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.95)OA: greenTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

K. Nathan Sankar ORCID,Garth W. Strohbehn ORCID,Lili Zhao ORCID,David J. Elliott ORCID,Angel Qin

Live enrichment

PubMed:34896803 PMC:PMC8770596 OpenAlex:https://openalex.org/W4200070918

NCI NIH HHS

Grant: R21 CA252010

NCI NIH HHS

Grant: R01 CA276217

BLRD VA

Grant: I01 BX005267

Melanoma Research Alliance

Department of Veterans Affairs

National Institutes of Health

LUNGevity Foundation

FWCI

1.95

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8770596

publisherhttps://api.elsevier.com/content/article/PII:S0169500221006280?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0169500221006280?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.lungcan.2021.11.021

Fields of Study

Inflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentCarcinoma, Non-Small-Cell LungHumansImmunotherapyLung NeoplasmsLymphocytesNeutrophilsPrognosis

MeSH Terms

Carcinoma, Non-Small-Cell LungHumansImmunotherapyLung NeoplasmsLymphocytesNeutrophilsPrognosis

Keywords

MedicinePredictive valueNeutrophil to lymphocyte ratioOncologyStage (stratigraphy)Lung cancerImmunotherapyInternal medicineAdjuvantLymphocyteImmunologyCancerStage IiiNeutrophil-to-lymphocyte RatioDurvalumabNon-small-cell

Sustainable Development Goals

SDG 0: Good health and well-being

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

FAIR Checklist

Authors (9)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)